FDA to review AstraZeneca and FibroGen's Roxadustat
(Sharecast News) - Pharmaceutical giant AstraZeneca said on Tuesday that the Food and Drug Administration will convene a meeting of its Cardiovascular and Renal Drugs Advisory Committee to review a new US drug application for Roxadustat.
